Skip to main content

Table 2 Dichotomous outcomes

From: N-acetylcysteine plus deferoxamine for patients with prolonged hypotension does not decrease acute kidney injury incidence: a double blind, randomized, placebo-controlled trial

Outcome Placebo (n = 40) NAC + DFX (n = 40) Relative risk, non-adjusted (95 % CI) Relative risk, adjusted (95 % CI)
AKI incidence 27 (67) 26 (65) 0.89 (0.35–2.2) 1.1 (0.37–3.2)
AKI severity, stages 2 and 3, n (%) 24 (60) 15 (37) 0.4 (0.16–0.98) 0.35 (0.13–0.93)
RRT, n (%) 6 (15) 6 (15) 1.0 (0.29–3.4) 1.1 (0.3–4.2)
ICU death, n (%) 21 (52) 23 (57) 1.22 (0.50–2.9) 1.6 (0.58–4.4)
Hospital death, n (%) 23 (57) 24 (60) 1.1 (0.45–2.7) 1.3 (0.51–3.7)
  1. NAC + DFX N-acetylcysteine plus deferoxamine, AKI acute kidney injury, RRT renal replacement therapy, ICU intensive care unit